Iscar for Supplemental Care in Stage IV Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00079794

Enrollment

Registered

2004-03-16

Start date

2001-09-30

Completion date

2004-02-29

Last updated

2008-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, herbal medicine, non-small cell cancer, Iscar, mistletoe

Brief summary

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Detailed description

See Brief Summary

Interventions

DRUGIscar

DRUGmistletoe

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria

* Known allergy to Viscum Album L. * Concomitant use of other mistletoe products * Concomitant use of mushroom glucan and proteoglycan extracts * Concomitant use of thymus extract products * Inability to self-report quality of life utilizing assessment tools * Ongoing steroid or ACTH therapy * Co-morbid immunocompromised state * Pregnancy * Participation in other clinical trials

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026